Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bone quality and bone metabolism (marker)].

Masao Fukunaga1

  • 1Department of Nuclear Medicine, Kawasaki Medical School.

Clinical Calcium
|December 4, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating α-Klotho Counteracts Transforming Growth Factor-β-Induced Sarcopenia.

The American journal of pathology·2023
Same author

Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene.

Calcified tissue international·2023
Same author

Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association·2020
Same author

Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.

Current medical research and opinion·2020
Same author

Executive summary of the Japan Osteoporosis Society Guide for the Use of Bone Turnover Markers in the Diagnosis and Treatment of Osteoporosis (2018 Edition).

Clinica chimica acta; international journal of clinical chemistry·2019
Same author

Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04.

Journal of bone and mineral metabolism·2018

Bone strength depends on density and quality, including bone turnover. Monitoring bone turnover markers can help reduce fracture risk with effective therapy.

Area of Science:

  • Orthopedics and Bone Biology
  • Biochemistry and Metabolism

Context:

  • Bone strength is determined by bone density and quality.
  • Bone quality encompasses architecture, turnover, damage accumulation, and mineralization.
  • Increased bone turnover is a significant risk factor for fractures, especially in individuals with low bone mineral density.

Purpose:

  • To elucidate the relationship between bone turnover markers and fracture risk.
  • To highlight the impact of therapeutic interventions on bone metabolic markers and fracture reduction.

Summary:

  • Bone strength is a composite of bone density and quality.
  • Elevated bone turnover, indicated by markers like urinary CTX, DPD, and PYD, or decreased turnover (serum ICTP), correlates with increased fracture risk.
  • Therapeutic reduction of bone metabolic markers by 50-70% is associated with a 40-44% decrease in fracture risk.

Related Experiment Videos

Impact:

  • Provides insights into fracture risk assessment beyond bone mineral density.
  • Emphasizes the clinical significance of monitoring bone turnover for fracture prevention strategies.
  • Suggests that targeted therapies can effectively mitigate fracture risk by modulating bone turnover.